CD19 and neoplasm: Interestingly, tumour-infiltrating B cells (B220+CD19+) were uniquely increased in RMC-4550 treated tumours along with an increase of tumour-infiltrating plasma cells (CD138+) (Fig. 6g), suggesting additional effects of SHP2 inhibition in the B cell populations.